Half-year report · HY
2590.TEDINET S100Z07E
Period2026-01-21 → 2026-07-20
Filed2026-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥120.1bn | 2026-01-21 → 2026-07-20 | Cons. | Net sales |
| Revenue | ¥241.2bn | 2025-01-21 → 2026-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.7bn | 2025-01-21 → 2025-07-20 | Cons. | Net sales |
| Operating income | ¥6.7bn | 2026-01-21 → 2026-07-20 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Operating income |
| Ordinary income | ¥4.3bn | 2026-01-21 → 2026-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2025-01-21 → 2026-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥4.3bn | 2026-01-21 → 2026-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2026-01-21 → 2026-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥30.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.9bn | 2026-01-21 → 2026-07-20 | Cons. | Profit loss |
| Net income | −¥1.9bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss |
| Total assets | ¥166.4bn | at 2026-07-20 | Cons. | Assets |
| Total assets | ¥162.8bn | at 2026-01-20 | Cons. | Assets |
| Total assets | ¥196.2bn | at 2025-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥96.6bn | at 2026-07-20 | Cons. | Liabilities |
| Total liabilities | ¥97.9bn | at 2026-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥69.8bn | at 2026-07-20 | Cons. | Net assets |
| Net assets / equity | ¥64.9bn | at 2026-01-20 | Cons. | Net assets |
| Net assets / equity | ¥90.7bn | at 2025-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥24.1bn | at 2026-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥28.0bn | at 2026-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥23.3bn | at 2026-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.9bn | at 2026-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.9bn | at 2025-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.9bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.4bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.8bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥12.1bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.2bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.4bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥300m | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥88.34 | 2026-01-21 → 2026-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-957.83 | 2025-01-21 → 2026-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-43.05 | 2025-01-21 → 2025-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.5% | at 2026-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.5% | at 2026-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2025-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-21 → 2026-07-20 | −¥121m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-21 → 2026-07-20 | −¥121m |
| Reconciling Itemsreconciling | segment profit | 2026-01-21 → 2026-07-20 | −¥821m |
| Domestic Beverage Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥67.6bn |
| Domestic Beverage Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥67.6bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥41m |
| Domestic Beverage Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥2.1bn |
| Dy Do Pharmareportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥473m |
| Dy Do Pharmareportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥473m |
| Dy Do Pharmareportable segment | segment profit | 2026-01-21 → 2026-07-20 | −¥80m |
| Food Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥9.5bn |
| Food Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥9.5bn |
| Food Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥3m |
| Food Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥35m |
| International Beverage Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥36.0bn |
| International Beverage Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥36.0bn |
| International Beverage Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥5.2bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥6.5bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥6.5bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥76m |
| Pharmaceutical Related Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥267m |
| —segment total | revenue | 2026-01-21 → 2026-07-20 | ¥120.2bn |
| —segment total | revenue external | 2026-01-21 → 2026-07-20 | ¥120.1bn |
| —segment total | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥121m |
| —segment total | segment profit | 2026-01-21 → 2026-07-20 | ¥7.6bn |
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2025-07-20 | −¥506m |
| Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥65m |
| Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥2.0bn |
| Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥263m |
| Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥263m |
| Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥184m |
| Food Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| Food Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥3m |
| Food Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥530m |
| International Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥3.1bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥7.0bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥6.8bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥158m |
| Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥463m |
| —segment total | revenue | 2025-01-21 → 2025-07-20 | ¥117.9bn |
| —segment total | revenue external | 2025-01-21 → 2025-07-20 | ¥117.7bn |
| —segment total | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥228m |
| —segment total | segment profit | 2025-01-21 → 2025-07-20 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 530
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | InterimDuration | 5249000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1InterimDuration | -536000000 | JPY |
| Comprehensive income attributable to non controlling interests | InterimDuration | 91000000 | JPY |
| Income before income taxes | Prior1InterimDuration | 69000000 | JPY |
| Income before income taxes | InterimDuration | 4331000000 | JPY |
| Depreciation and amortization ope cf | Prior1InterimDuration | 5399000000 | JPY |
| Depreciation and amortization ope cf | InterimDuration | 2788000000 | JPY |
| Amortization of goodwill ope cf | Prior1InterimDuration | 317000000 | JPY |
| Amortization of goodwill ope cf | InterimDuration | 347000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | Prior1InterimDuration | 1000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | InterimDuration | 1000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1InterimDuration | 10000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | InterimDuration | 4000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1InterimDuration | 136000000 | JPY |
| Increase decrease in provision for bonuses ope cf | InterimDuration | 175000000 | JPY |
| Increase decrease in provision for share based remuneration for directors and other officers ope cf | Prior1InterimDuration | -24000000 | JPY |
| Increase decrease in provision for share based remuneration for directors and other officers ope cf | InterimDuration | － | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1InterimDuration | 30000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | InterimDuration | 17000000 | JPY |
| Interest and dividends income ope cf | Prior1InterimDuration | -462000000 | JPY |
| Interest and dividends income ope cf | InterimDuration | -672000000 | JPY |
| Interest expenses ope cf | Prior1InterimDuration | 543000000 | JPY |
| Interest expenses ope cf | InterimDuration | 677000000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1InterimDuration | 10000000 | JPY |
| Equity in earnings losses of affiliates ope cf | InterimDuration | 38000000 | JPY |
| Losses on net monetary position ope cf | Prior1InterimDuration | 668000000 | JPY |
| Losses on net monetary position ope cf | InterimDuration | 2466000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | -10406000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | -5828000000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -3061000000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -1899000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1InterimDuration | 9799000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | InterimDuration | -37000000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1InterimDuration | 1997000000 | JPY |
| Increase decrease in accounts payable other ope cf | InterimDuration | 1693000000 | JPY |
| Decrease increase in other assets ope cf | Prior1InterimDuration | -525000000 | JPY |
| Decrease increase in other assets ope cf | InterimDuration | -1298000000 | JPY |
| Increase decrease in other liabilities ope cf | Prior1InterimDuration | 323000000 | JPY |
| Increase decrease in other liabilities ope cf | InterimDuration | 212000000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | 4827000000 | JPY |
| Subtotal ope cf | InterimDuration | 3017000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 454000000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 679000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -539000000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -677000000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -2598000000 | JPY |
| Income taxes paid ope cf | InterimDuration | -1141000000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 2143000000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | 1877000000 | JPY |
| Payments into time deposits inv cf | Prior1InterimDuration | -3073000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |